Shots: The P-IIb VISION-DMD study involves assessing the efficacy & safety of vamorolone (2&6 mg/kg/day) vs PBO and prednisone (0.75 mg/kg/day) in 121 ambulant boys aged 4 to <7 years […]readmore
Tags : ReveraGen
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Shots: Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement. Santhera to get an exclusive license, including […]readmore